An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of ...

A double-blind randomized phase 3 clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several ...

Aligos Therapeutics, Inc. (ALGS), a clinical stage biopharmaceutical company focused on liver and viral diseases, announced Thursday ...

The blinded blood pressure monitor and scale allows blind data monitoring, where participants can take readings but not see ...

For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

The FDA has lifted a clinical hold on a Peninsula company's hyperinsulinism trial, allowing study to start early next year.

The absence of “trip” effects could allow for more reliable double-blind trials, an essential element in gaining FDA approval. The company recently announced that PSIL-006 had successfully ...

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted)Well-tolerated with no treatment-related dose ...